There are no currently accepted evidence-based guidelines for the diagnosis and management of the normal-pressure hydrocephalus (NPH) patient. As a result, an independent study group was assembled to address this issue and determine the feasibility of developing standardized guidelines, which would be acceptable in the United States and abroad and would be based on the available scientific evidence. The guidelines were to encompass value of clinical presentation, value of supplementary diagnostic tests, surgical management, and outcome assessment. METHODS: Initially, a series of 10 questions were formulated in the areas of pathophysiology, diagnosis, and treatment to obtain a consensus by panels of experts (see Acknowledgments) assembled in San Antonio, TX, in September 2000. This workshop provided significant insight into the difficulties in developing NPH guidelines, and a consensus was reached as to those questions involving expert opinion. Subsequently, evidentiary tables were developed on the basis of the available evidence. Only those studies with 20 or more idiopathic NPH (INPH) patients were included. RESULTS: Sensitivity, specificity, and positive and negative predictive values for INPH diagnostic criteria were assessed, and guidelines were developed on the basis of the available evidence. Recommendations for classification of INPH and additional studies were documented. CONCLUSION: The development of the guidelines was made difficult because systematic studies of INPH and patient numbers were few. It was decided to maintain the classification of NPH into two major categories, INPH and those of known cause (secondary NPH). Many studies "mixed" these classifications, and as a result, they could not be used in the evidentiary tables. Despite these problems, evidence-based guidelines were developed, and it is hoped that they will be useful in guiding clinical management of the INPH patient.
In the English-language literature, NPH was introduced in the landmark article by Adams et al. (1) published in the New England Journal of Medicine in 1965. Hakim appears as a coauthor. They are credited with identifying a specific syndrome associated with patients in whom ventricular enlargement occurred in the absence of elevated intracranial pressure and who presented with gait disturbance, dementia, and incontinence. In an article by Hakim and Adams (4) published in 1965, three case reports described ventriculomegaly developing in three cases, two posttraumatic and one idiopathic. Hakim went on to describe the "classic triad" of gait disturbance, incontinence, and dementia, which were improved with removal of cerebrospinal fluid.
Since that time, considerable controversy has evolved as to the appropriate diagnosis and management of the NPH patient, in part because of the "mixing" of idiopathic NPH (INPH) patients (primary NPH) with those with NPH of known cause (secondary NPH), such as trauma, subarachnoid hemorrhage, and stroke. Although no epidemio-logical data exist, the numbers of both INPH and secondary NPH patients in many neurological and neurosurgical services are increasing, most likely because of improved health care and increased longevity. From our own experience, patients in their 80s are now seeking an improved quality of life and are willing to accept the risks of surgery. However, despite several thousand articles published in the field of NPH, there are no currently accepted evidencebased guidelines for the diagnosis and management of the INPH patient. As a result, an independent study group was assembled to address this issue and determine the feasibility of developing standardized guidelines that would be acceptable here and abroad and would be based on the available scientific evidence.
First, it was decided that the initial set of guidelines should refer to the diagnosis and management of primary NPH or INPH. It was thought that this subdivision would help simplify the diagnostic approach, because the potential for recovery in INPH patients would be less influenced by comorbid factors. In the process of guideline development, we were to learn that comorbidity is not exclusive to secondary NPH but rather is equally important in an INPH population in which the median age is 70 years or more. Nevertheless, we maintained this exclusion in the development of the INPH guidelines, because it was shown that the nature of the relevant comorbid factors was clearly different, and subjects not covered in the present effort will be considered for future study.
The major goal of these guidelines is to provide the best scientific basis for current clinical practice. In the absence of randomized trials, most scientific evidence in the field of NPH is insufficient for standards of care; however, as a result of this effort, recommendations are made to implement well-designed clinical trials so that eventually, many of the options presented in this report can be moved to guideline status in the future.
PROCESS USED IN DEVELOPMENT OF GUIDELINES
The guidelines cover four major topics, which include the clinical diagnosis of INPH, the value of supplementary diagnostic tests, surgical management, and outcome. In September 2000, an NPH independent study group consisting of five members was assembled to initiate the task of guideline development. Codman, a division of Johnson & Johnson, agreed to fund this enormous task by providing meeting venues for national and international consultants and agreed not to participate in any aspect of guideline formulation to avoid conflict of interest. This agreement was honored throughout the development procedure.
Initially, a series of 10 questions, each posed in regard to the topics of pathophysiology, diagnosis, and treatment, was formulated by the study group to obtain a consensus by panels of experts (see Acknowledgments) assembled in San Diego, CA, in February 2001. This workshop provided significant insight into the difficulties in developing INPH guidelines, and a consensus was reached as to those questions involving expert opinion. Subsequently, each member of the independent study group was assigned a topic and proceeded to develop the evidentiary tables and a preliminary report. After several meetings of the independent study group, the tables were reviewed, modified, and refined, and a set of preliminary guidelines was formulated. The consensus was presented at several international meetings and congresses to a new group of investigators, finally updated, and presented during the International Hydrocephalus Workshop in Kos, Greece, in May 2001. In addition, the preliminary guidelines were presented to a European review board in Hannover, Germany, in November 2001 (see Acknowledgments), where each member was asked to review them and provide recommendations so that the guidelines would reflect the experience of our European colleagues. The guidelines were also presented at two meetings in Japan to the NPH committee of the Japanese Neurosurgical Society, who reviewed the guidelines and agreed in principle as to their formulation. Subsequently, having the feedback of both European and Asian colleagues in hand, each member of the study group was assigned one topic and proceeded toward further refinement of the evidentiary tables and the article on the basis of existing medical evidence. Through a process of draft after draft interchange among the independent study group members, the current INPH guidelines presented in this report were formed.
TERMINOLOGY Classification of Guidelines
Guidelines are subdivided into three major categories: Standards, Guidelines, and Options. The accepted definition of these categories is as follows (2) .
Standard: accepted principles of management that reflect a high degree of clinical certainty. Guideline: a particular strategy or range of management strategies that reflect a moderate clinical certainty. Options: remaining strategies for patient management for which there is unclear clinical certainty.
Accuracy of Supplemental Tests
The ability of supplemental tests, such as a "tap test," to identify INPH patients who would benefit from a shunt is quantified in terms of sensitivity, specificity, positive predictive value, negative predictive value, and accuracy. These terms are usually applied in cases in which the true disease outcome is known. However, they are frequently used in practice to compare a test against some standard test, which is usually assumed to be correct. In this case, a positive response to shunting is the test that may be considered a standard test for assessing the ability of a supplemental procedure, such as the tap test, to predict a positive shunt response. The definitions of these terms used throughout the articles are as follows. 
Classification of Evidence
The assessment as to the "class" of evidence is critical to the guideline development, because it is the assignment of class that determines the level of certainty regarding a management principle. The classes of evidence are defined below.
Class I Evidence: derived from prospective, randomized, well-controlled clinical trials. Standards are generally based on strong Class I evidence. However, strong Class II data may be used if the form of management cannot be randomized (e.g., studies in cardiac resuscitation).
Class II Evidence: prospective data collection with retrospective analysis of clearly reliable data. These studies would include observational studies, cohort studies, prevalence studies, and case-control studies. This Class II evidence or a preponderance of Class III evidence generally supports the "guidelines" category.
Class III Evidence: studies based on retrospective analysis, such as chart reviews, clinical series, databases or registries, case reports, and expert opinion. This level of evidence generally supports the "options" category and is useful in guiding future studies and for educational purposes.
SUMMARY
Evidence-based guidelines are the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of the individual patient. The current guidelines put forth in these articles were formulated with this objective in mind. Clearly, there are several areas in which additional studies are necessary to help clarify or improve our current understanding in areas of diagnosis and management. Thus, we consider these guidelines a "dynamic" work, which will be improved as additional evidence and information is provided.
Disclaimer of Liability
The information in these guidelines reflects the current state of knowledge at the time of completion in June 2003. The information is designed to provide accurate and authoritative information in regard to the subject matter covered. It is anticipated that future developments in science and technology will require periodic review and updating of these guidelines. These guidelines are distributed with the understanding that the authors and consultants who have collaborated in the development of these guidelines are not engaged in rendering medical services. If medical advice or assistance is required, the services of a competent physician should be sought. The recommendations contained in these guidelines may not be appropriate for use in all circumstances. The decision to adopt any particular recommendation contained in these guidelines must be made by a treating physician in light of the circumstances in each particular patient and on the basis of available resources.
